COMP <GO>
BRVE vs XERS // 10Y YIELD & FRED MACRO BETA
Braveheart Bio Inc. (NASDAQ) VS. Xeris Biopharma Holdings Inc. (NASDAQ) • 15-METRIC TALLY: BRVE 0
— XERS 2
■ METRIC PARITY
LAST: $21.19 (-2.62%) • MKT CAP: $1.91B
macro-sensitivity
—
LAST: $10.75 (+1.03%) • MKT CAP: $1.96B
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BRVE VS. XERS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BRVE | XERS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 16.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 83.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 1.46% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 8.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 0.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 43.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.11 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 60.0 | -10.82 | XERS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.91B | $1.96B | -$52.0M | XERS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BRVE REV | XERS REV | BRVE GROSS % | XERS GROSS % | BRVE FCF | XERS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $291.8M | — | — | — | $28.6M |
| FY 2024 | — | $203.1M | — | — | — | -$37.0M |
| FY 2023 | — | $163.9M | — | — | — | -$47.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BRVE // BETA —
XERS // BETA —